Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Tax Provisions (2024 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Tax Provisions for 2 consecutive years, with -$34794.0 as the latest value for Q4 2025.

  • On a quarterly basis, Tax Provisions fell 399.72% to -$34794.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$417375.0, a N/A change, with the full-year FY2025 number at -$468366.0, down 436.38% from a year prior.
  • Tax Provisions was -$34794.0 for Q4 2025 at Neuphoria Therapeutics, roughly flat from -$34793.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $11609.0 in Q4 2024 to a low of -$266602.0 in Q2 2025.